Regeneron and Columbia University Collaborate to Discover Monoclonal Antibodies
Posted on: Wednesday, 17 September 2008, 12:00 CDT
US-based biopharmaceutical company Regeneron Pharmaceuticals and Columbia University have signed an agreement that will provide researchers at Columbia University Medical Center with access to Regeneron's VelocImmune technology to discover fully human monoclonal antibodies.
Under the agreement, scientists at Columbia will use VelocImmune mice to generate antibodies against their research targets and will conduct research to discover potential human therapeutics based on the antibodies. Regeneron has an exclusive option to license the antibodies for development and commercialization as therapeutic or diagnostic products.
George Yancopoulos, president of Regeneron Research Laboratories, said: "VelocImmune is the only antibody platform that allows researchers with limited antibody-production resources to create high affinity, well-expressing, fully human antibodies in their own laboratories.
"Participation in the academic VelocImmune Investigators Program gives university scientists the unique opportunity to translate their research, insights, and discoveries directly into potential antibody therapeutics for the treatment of human diseases."
Source: Datamonitor
Related Articles
- Nu Skin Announces Research Agreements With Stanford University and LifeGen Technologies
- Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
- Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem
- BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
- ADVR Announces Research Collaboration With Northeastern University
- Samaritan Therapeutics Signs Research Collaboration and Licensing Agreement With The Research Institute of McGill University Health Centre; Collaboration to Advance Pipeline Into Clinical Trials and Develop New Innovative Drugs
- Xpention Genetics Extends Research Agreement With The University of Texas Health Science Center at San Antonio
- AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies
- PacificHealth Laboratories Awards Research Grant to Manchester University
- Life's Solution: Inevitable Humans in a Lonely Universe
 |
 |
User Comments (0)
RSS Feeds